Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Rochester National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00040742 |
RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy.
PURPOSE: This randomized phase II/III trial is studying giving antiemetic drugs together with ginger to see how well they work compared to antiemetic drugs alone in treating nausea in patients who are receiving chemotherapy for cancer.
Condition | Intervention | Phase |
---|---|---|
Nausea and Vomiting Unspecified Adult Solid Tumor, Protocol Specific |
Dietary Supplement: ginger extract Other: placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Double-Blind, Placebo Control |
Official Title: | A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer |
Estimated Enrollment: | 706 |
Study Start Date: | March 2003 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm I: Placebo Comparator
Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
|
Other: placebo
Given orally
|
Arm II: Experimental
Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
|
Dietary Supplement: ginger extract
Given orally
Other: placebo
Given orally
|
Arm III: Experimental
Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
|
Dietary Supplement: ginger extract
Given orally
Other: placebo
Given orally
|
Arm IV: Experimental
Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
|
Dietary Supplement: ginger extract
Given orally
|
OBJECTIVES:
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 4 treatment arms. Day 1 of each course is defined as the day of chemotherapy administration.
Patients in each arm also continue receiving their scheduled antiemetic regimen comprising a 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist (ondansetron, granisetron, tropisetron, and dolasetron mesylate) and dexamethasone (DM) (or the equivalent dose of IV methylprednisolone (MePRDL)) on day
1 of courses 2 and 3.
Symptoms are assessed on day -3 to day 1 of courses 2 and 3 and on days 1-4 of courses 1-3.
Quality of life is assessed on day 4 of courses 1-3.
Nausea and vomiting are assessed 4 times daily on days 1-4 of courses 1-3.
PROJECTED ACCRUAL: A total of 706 patients will be accrued for this study within 3 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of cancer and be scheduled to receive at least 3 courses of chemotherapy
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Alabama | |
MBCCOP - Gulf Coast | |
Mobile, Alabama, United States, 36606 | |
United States, Hawaii | |
MBCCOP - Hawaii | |
Honolulu, Hawaii, United States, 96813 | |
United States, Illinois | |
CCOP - Central Illinois | |
Decatur, Illinois, United States, 62526 | |
MBCCOP - University of Illinois at Chicago | |
Chicago, Illinois, United States, 60612-7323 | |
United States, Kansas | |
CCOP - Wichita | |
Wichita, Kansas, United States, 67214-3882 | |
United States, Michigan | |
CCOP - Grand Rapids | |
Grand Rapids, Michigan, United States, 49503 | |
CCOP - Kalamazoo | |
Kalamazoo, Michigan, United States, 49007-3731 | |
United States, Minnesota | |
CCOP - Metro-Minnesota | |
St. Louis Park, Minnesota, United States, 55416 | |
United States, Missouri | |
CCOP - Kansas City | |
Kansas City, Missouri, United States, 64131 | |
United States, Nevada | |
CCOP - Nevada Cancer Research Foundation | |
Las Vegas, Nevada, United States, 89106 | |
United States, New York | |
CCOP - Hematology-Oncology Associates of Central New York | |
East Syracuse, New York, United States, 13057 | |
CCOP - North Shore University Hospital | |
Manhassett, New York, United States, 11030 | |
United States, North Carolina | |
CCOP - Southeast Cancer Control Consortium | |
Goldsboro, North Carolina, United States, 27534-9479 | |
United States, Ohio | |
CCOP - Columbus | |
Columbus, Ohio, United States, 43215 | |
United States, Oregon | |
CCOP - Columbia River Oncology Program | |
Portland, Oregon, United States, 97225 | |
United States, South Carolina | |
CCOP - Greenville | |
Greenville, South Carolina, United States, 29615 | |
CCOP - Upstate Carolina | |
Spartanburg, South Carolina, United States, 29303 | |
United States, Washington | |
CCOP - Northwest | |
Tacoma, Washington, United States, 98405-0986 | |
United States, Wisconsin | |
CCOP - Marshfield Clinic Research Foundation | |
Marshfield, Wisconsin, United States, 54449 |
Study Chair: | Julie L. Ryan, PhD, MPH | University of Rochester |
Study ID Numbers: | CDR0000069401, URCC-U1902, URCC-0114, NCI-5857, NCI-P02-0223 |
Study First Received: | July 8, 2002 |
Last Updated: | February 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00040742 History of Changes |
Health Authority: | United States: Federal Government |
nausea and vomiting unspecified adult solid tumor, protocol specific |
Signs and Symptoms Vomiting Signs and Symptoms, Digestive Nausea |
Signs and Symptoms Vomiting Signs and Symptoms, Digestive Nausea |